BlueRock Therapeutics
Clinical trials sponsored by BlueRock Therapeutics, explained in plain language.
A cell therapy company developing treatments for neurological and cardiac diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Brain cell transplant trial aims to give Parkinson's patients more good hours each day Results expected Mar 2027 (estimated)
-
Stem cell eye treatment could restore sight in retinal disease patients
Disease control Recruiting nowThis study tests a new treatment called OpCT-001 for people with inherited eye diseases that damage the retina, such as retinitis pigmentosa. The treatment involves injecting special photoreceptor cells, made from stem cells, into the back of the eye to replace lost cells. The tr…
Phase 1/2 • Sponsor: BlueRock Therapeutics • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Brain cell transplant trial aims to give Parkinson's patients more good hours each day
Disease control Recruiting nowThis study tests a treatment called bemdaneprocel, which involves transplanting dopamine-producing nerve cells into the brains of people with Parkinson's disease. The goal is to reduce daily 'OFF' time—when symptoms return—and increase 'ON' time without uncontrolled movements. Ab…
Phase 3 • Sponsor: BlueRock Therapeutics • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC